Scientists test novel combo against Tough-to-Treat tumors
NCT ID NCT05661201
Summary
This early-stage trial is testing the safety and initial effectiveness of a new two-drug combination (NEROFE plus doxorubicin) for patients with advanced solid tumors that have specific genetic markers (KRAS mutation and ST2 protein). The main goal is to find the safest dose and schedule for weekly treatment. It will enroll 24 adults who have run out of standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
RECRUITINGWashington D.C., District of Columbia, 20007, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.